mitomycin has been researched along with Mesothelioma in 49 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Mesothelioma: A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a multicenter phase II trial to evaluate the impact on the activity, efficacy, symptom control and safety of using two active regimens in a sequential schedule (cisplatin/gemcitabine followed by mitoxantrone/methotrexate/mitomycin) as first-line chemotherapy for unresectable malignant pleural mesothelioma (MPM)." | 9.12 | Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1). ( Benedetti, G; De Pangher Manzini, V; Del Conte, G; dell'Amore, D; Galetta, D; Giaquinta, S; Lopez, M; Marino, A; Martoni, A; Mazzanti, P; Piana, E; Pinto, C, 2006) |
| "Between October 1986 and May 2002 all patients with inoperable pleural mesothelioma were considered for treatment with MVP (mitomycin C 8 mg/m2 every 6 weeks, vinblastine 6 mg/m2 every 3 weeks and cisplatin 50 mg/m2 every 3 weeks) chemotherapy." | 9.11 | The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. ( Andreopoulou, E; Ashley, S; Eisen, T; Ford, HE; Norton, A; O'Brien, ME; Priest, K; Ross, PJ; Smith, IE, 2004) |
| "Between October 1986 and June 1997, 39 patients with advanced inoperable malignant mesothelioma were treated with palliative MVP (mitomycin-C 8 mg/m2 q." | 9.08 | Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. ( Ashley, S; Hickish, T; Middleton, GW; Norton, A; O'Brien, ME; Priest, K; Smith, IE; Spencer, L, 1998) |
| "Twelve patients with malignant pleural mesothelioma were subjected to mitomycin C (MMC) and vindesine (VDS) chemotherapy (MMC 10 mg/m2, i." | 7.68 | Mitomycin C and vindesine: an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma. ( Airoma, G; Bianco, AR; Gridelli, C; Incoronato, P; Palazzolo, G; Pepe, R; Rossi, A, 1992) |
| " Twenty-one patients with PC (12 gastric cancer, 5 colorectal cancer, 2 ovarian cancer, 1 pseudomyxoma peritonei, 1 malignant mesothelioma) were treated with CRS + HIPEC with hydroxycamptothecin 20 mg and mitomycin C 30 mg in 12,000 mL of normal saline at 43 +/- ." | 5.14 | Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. ( al-shammaa Hassan, AH; Li, Y; Liu, SY; Lu, YL; Yang, GL; Yang, XJ; Yonemura, Y; Zhang, JW, 2009) |
| "We performed a multicenter phase II trial to evaluate the impact on the activity, efficacy, symptom control and safety of using two active regimens in a sequential schedule (cisplatin/gemcitabine followed by mitoxantrone/methotrexate/mitomycin) as first-line chemotherapy for unresectable malignant pleural mesothelioma (MPM)." | 5.12 | Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1). ( Benedetti, G; De Pangher Manzini, V; Del Conte, G; dell'Amore, D; Galetta, D; Giaquinta, S; Lopez, M; Marino, A; Martoni, A; Mazzanti, P; Piana, E; Pinto, C, 2006) |
| "Between October 1986 and May 2002 all patients with inoperable pleural mesothelioma were considered for treatment with MVP (mitomycin C 8 mg/m2 every 6 weeks, vinblastine 6 mg/m2 every 3 weeks and cisplatin 50 mg/m2 every 3 weeks) chemotherapy." | 5.11 | The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. ( Andreopoulou, E; Ashley, S; Eisen, T; Ford, HE; Norton, A; O'Brien, ME; Priest, K; Ross, PJ; Smith, IE, 2004) |
| "The objectives of this study were to determine the toxicity of intratumoural/intrapleural SRL172 in addition to intradermal SRL172 and standard chemotherapy (mitomycin-C, vinblastine and cisplatin) in patients with malignant mesothelioma." | 5.10 | Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma. ( Ashley, S; Bromelow, KV; Gregory, RK; Mendes, R; Mitra, A; Norton, A; O'Brien, ME; Padhani, AR; Smith, IE; Souberbielle, BE; Winkley, AR, 2002) |
| "Between October 1986 and June 1997, 39 patients with advanced inoperable malignant mesothelioma were treated with palliative MVP (mitomycin-C 8 mg/m2 q." | 5.08 | Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. ( Ashley, S; Hickish, T; Middleton, GW; Norton, A; O'Brien, ME; Priest, K; Smith, IE; Spencer, L, 1998) |
| " More than 50% of centers administer oxaliplatin (74%), or mitomycin-C (65%) in colorectal cancer; cisplatin in gastric cancer (73%) and mesothelioma (74%)." | 3.88 | Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey. ( Barrios, P; Cascales-Campos, P; Esteve-Pérez, N; Morales-Soriano, R; Segura-Sampedro, JJ, 2018) |
| "Twelve patients with malignant pleural mesothelioma were subjected to mitomycin C (MMC) and vindesine (VDS) chemotherapy (MMC 10 mg/m2, i." | 3.68 | Mitomycin C and vindesine: an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma. ( Airoma, G; Bianco, AR; Gridelli, C; Incoronato, P; Palazzolo, G; Pepe, R; Rossi, A, 1992) |
| "To evaluate the tolerance of peritonectomy procedures (PP) combined with intraperitoneal chemohyperthermia (IPCH) in patients with peritoneal carcinomatosis (PC), a phase II study was carried out from January 1998 to September 2001." | 2.71 | Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. ( Beaujard, AC; Francois, Y; Freyer, G; Gilly, FN; Glehen, O; Guertsch, P; Mithieux, F; Osinsky, D; Panteix, G; Peyrat, P; Vignal, J, 2003) |
| "Malignant pleural mesothelioma is associated with a poor prognosis because of its resistance to treatment." | 2.69 | Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura. ( Astoul, P; Boutin, C; Kasseyet, S, 1999) |
| " 28 evaluable patients with previously untreated symptomatic NSCLC and mesothelioma were randomized to receive either 3 weekly intravenous combination chemotherapy alone, or chemotherapy given with monthly intra-dermal injections of SRL172." | 2.69 | A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. ( Bromelow, KV; Gregory, K; Kennard, DA; Mendes, R; O'Brien, ME; Palmer, RD; Priest, K; Ryan, C; Saini, A; Smith, IE; Souberbielle, BE; Tuckwell, N; Webb, A, 2000) |
| "Bibasilar atelectasis and pleural effusions are common findings after IPHC with MMC, but most of them do not necessarily warrant intervention." | 2.68 | Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery. ( Chen, MY; Chiles, C; Choplin, RH; Fleming, RA; Loggie, BW; Perini, MA, 1997) |
| "Patients with PC from colorectal or appendiceal cancer, pseudomyxoma peritonei or malignant peritoneal mesothelioma referred to the single national HIPEC centre were prospectively registered from June 2006 to July 2012." | 1.39 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience. ( Hagemann-Madsen, R; Iversen, LH; Laurberg, S; Rasmussen, PC, 2013) |
| "Mean time to disease progression was 2." | 1.39 | Nonselective transarterial chemoperfusion: a palliative treatment for malignant pleural mesothelioma. ( Gurung, J; Lindemayr, S; Mbalisike, EC; Naguib, NN; Nour-Eldin, NE; Vogl, TJ; Zangos, S, 2013) |
| "We conclude that minimal residual disease, compared with macroscopically complete cytoreduction, correlated to failure in critical anatomical areas, suggesting the need for maximal cytoreductive surgical efforts." | 1.35 | Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). ( Baratti, D; Cabras, AD; Deraco, M; Dileo, P; Kusamura, S; Laterza, B, 2009) |
| "Peritoneal mesothelioma is a rare disease with few therapeutic options." | 1.33 | Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. ( Brigand, C; Gilly, FN; Glehen, O; Isaac, S; Mohamed, F; Monneuse, O; Sayag-Beaujard, AC, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (8.16) | 18.7374 |
| 1990's | 8 (16.33) | 18.2507 |
| 2000's | 20 (40.82) | 29.6817 |
| 2010's | 13 (26.53) | 24.3611 |
| 2020's | 4 (8.16) | 2.80 |
| Authors | Studies |
|---|---|
| Baron, C | 1 |
| Buchholz, M | 1 |
| Majchrzak-Stiller, B | 1 |
| Peters, I | 1 |
| Fein, D | 1 |
| Müller, T | 1 |
| Uhl, W | 1 |
| Höhn, P | 1 |
| Strotmann, J | 1 |
| Braumann, C | 1 |
| Forsythe, SD | 1 |
| Erali, RA | 1 |
| Edenhoffer, N | 1 |
| Meeker, W | 1 |
| Wajih, N | 1 |
| Schaaf, CR | 1 |
| Laney, P | 1 |
| Vanezuela, CD | 1 |
| Li, W | 1 |
| Levine, EA | 2 |
| Soker, S | 1 |
| Votanopoulos, KI | 1 |
| Arjona-Sanchez, A | 1 |
| Aziz, O | 1 |
| Passot, G | 3 |
| Salti, G | 2 |
| Esquivel, J | 1 |
| Van der Speeten, K | 1 |
| Piso, P | 1 |
| Nedelcut, DS | 1 |
| Sommariva, A | 1 |
| Yonemura, Y | 2 |
| Turaga, K | 1 |
| Selvasekar, CR | 1 |
| Rodriguez-Ortiz, L | 1 |
| Sanchez-Hidalgo, JM | 1 |
| Casado-Adam, A | 1 |
| Rufian-Peña, S | 1 |
| Briceño, J | 1 |
| Glehen, O | 4 |
| Zahid, A | 1 |
| Clarke, L | 1 |
| Carr, N | 1 |
| Chandrakumaran, K | 2 |
| Tzivanakis, A | 1 |
| Dayal, S | 1 |
| Mohamed, F | 3 |
| Cecil, T | 2 |
| Moran, BJ | 1 |
| Morales-Soriano, R | 1 |
| Esteve-Pérez, N | 1 |
| Segura-Sampedro, JJ | 1 |
| Cascales-Campos, P | 1 |
| Barrios, P | 1 |
| Malgras, B | 1 |
| Gayat, E | 1 |
| Aoun, O | 1 |
| Lo Dico, R | 1 |
| Eveno, C | 1 |
| Pautrat, K | 1 |
| Delhorme, JB | 1 |
| Marchal, F | 1 |
| Sgarbura, O | 1 |
| Ferron, G | 1 |
| Goéré, D | 1 |
| Andre, T | 1 |
| Pocard, M | 1 |
| Iversen, LH | 1 |
| Rasmussen, PC | 1 |
| Hagemann-Madsen, R | 1 |
| Laurberg, S | 1 |
| Baratti, D | 4 |
| Kusamura, S | 5 |
| Cabras, AD | 2 |
| Bertulli, R | 2 |
| Hutanu, I | 1 |
| Deraco, M | 5 |
| Magge, D | 1 |
| Zenati, MS | 1 |
| Austin, F | 1 |
| Mavanur, A | 1 |
| Sathaiah, M | 1 |
| Ramalingam, L | 1 |
| Jones, H | 1 |
| Zureikat, AH | 1 |
| Holtzman, M | 1 |
| Ahrendt, S | 1 |
| Pingpank, J | 1 |
| Zeh, HJ | 1 |
| Bartlett, DL | 1 |
| Choudry, HA | 1 |
| Bakrin, N | 1 |
| Roux, AS | 1 |
| Vaudoyer, D | 1 |
| Gilly, FN | 3 |
| Cotte, E | 1 |
| Shetty, SJ | 1 |
| Bathla, L | 1 |
| Govindarajan, V | 1 |
| Thomas, P | 1 |
| Loggie, BW | 2 |
| Bhagwandin, S | 1 |
| Naffouje, S | 1 |
| Moran, B | 1 |
| Arnold, S | 1 |
| Venkatasubramaniam, A | 1 |
| Huang, Y | 1 |
| Alzahrani, NA | 1 |
| Liauw, W | 1 |
| Morris, DL | 1 |
| Yang, XJ | 1 |
| Li, Y | 1 |
| al-shammaa Hassan, AH | 1 |
| Yang, GL | 1 |
| Liu, SY | 1 |
| Lu, YL | 1 |
| Zhang, JW | 1 |
| Dileo, P | 1 |
| Laterza, B | 1 |
| Blackham, AU | 1 |
| Shen, P | 1 |
| Stewart, JH | 1 |
| Russell, GB | 1 |
| Rueth, NM | 1 |
| Murray, SE | 1 |
| Huddleston, SJ | 1 |
| Abbott, AM | 1 |
| Greeno, EW | 1 |
| Kirstein, MN | 1 |
| Tuttle, TM | 1 |
| Vogl, TJ | 1 |
| Lindemayr, S | 1 |
| Naguib, NN | 1 |
| Gurung, J | 1 |
| Nour-Eldin, NE | 1 |
| Zangos, S | 1 |
| Mbalisike, EC | 1 |
| Ruffié, P | 2 |
| Mithieux, F | 1 |
| Osinsky, D | 1 |
| Beaujard, AC | 1 |
| Freyer, G | 1 |
| Guertsch, P | 1 |
| Francois, Y | 1 |
| Peyrat, P | 1 |
| Panteix, G | 1 |
| Vignal, J | 1 |
| Casali, P | 2 |
| Inglese, MG | 1 |
| Pennacchioli, E | 1 |
| Andreopoulou, E | 1 |
| Ross, PJ | 1 |
| O'Brien, ME | 4 |
| Ford, HE | 1 |
| Priest, K | 3 |
| Eisen, T | 1 |
| Norton, A | 3 |
| Ashley, S | 3 |
| Smith, IE | 4 |
| Fennell, DA | 2 |
| Parmar, A | 1 |
| Shamash, J | 2 |
| Evans, MT | 2 |
| Sheaff, MT | 2 |
| Sylvester, R | 1 |
| Dhaliwal, K | 1 |
| Gower, N | 1 |
| Steele, J | 1 |
| Rudd, R | 1 |
| Sugarbaker, PH | 2 |
| Nonaka, D | 1 |
| Rosai, J | 1 |
| Younan, R | 1 |
| Salvatore, A | 1 |
| Cabras Ad, AD | 1 |
| Brigand, C | 1 |
| Monneuse, O | 1 |
| Sayag-Beaujard, AC | 1 |
| Isaac, S | 1 |
| Pinto, C | 2 |
| Marino, A | 2 |
| De Pangher Manzini, V | 1 |
| Benedetti, G | 1 |
| Galetta, D | 1 |
| Mazzanti, P | 1 |
| Del Conte, G | 1 |
| dell'Amore, D | 1 |
| Piana, E | 2 |
| Giaquinta, S | 1 |
| Lopez, M | 1 |
| Martoni, A | 2 |
| Yan, TD | 1 |
| Stuart, OA | 1 |
| Yoo, D | 1 |
| De Simone, M | 1 |
| Rossi, CR | 1 |
| Cavaliere, F | 1 |
| Difilippo, F | 1 |
| Scuderi, S | 1 |
| Pilatti, P | 1 |
| Steele, JP | 1 |
| Wells, P | 1 |
| Rudd, RM | 1 |
| Stebbing, J | 1 |
| Hesdorffer, ME | 1 |
| Chabot, JA | 1 |
| Keohan, ML | 1 |
| Fountain, K | 1 |
| Talbot, S | 1 |
| Gabay, M | 1 |
| Valentin, C | 1 |
| Lee, SM | 1 |
| Taub, RN | 1 |
| Chahinian, AP | 2 |
| Norton, L | 1 |
| Holland, JF | 2 |
| Szrajer, L | 2 |
| Hart, RD | 1 |
| Rice, TW | 1 |
| Adelstein, DJ | 1 |
| Kirby, TJ | 1 |
| Saltarelli, MG | 1 |
| Murthy, SR | 1 |
| Van Kirk, MA | 1 |
| Wiedemann, HP | 1 |
| Weick, JK | 1 |
| Sauter, ER | 1 |
| Langer, C | 1 |
| Coia, LR | 1 |
| Goldberg, M | 1 |
| Keller, SM | 1 |
| Hastürk, S | 1 |
| Tastepe, I | 1 |
| Unlü, M | 1 |
| Cetin, G | 1 |
| Baris, YI | 1 |
| Chen, MY | 1 |
| Chiles, C | 1 |
| Choplin, RH | 1 |
| Perini, MA | 1 |
| Fleming, RA | 1 |
| Middleton, GW | 1 |
| Hickish, T | 1 |
| Spencer, L | 1 |
| Kasseyet, S | 1 |
| Astoul, P | 1 |
| Boutin, C | 1 |
| Fizazi, K | 1 |
| Caliandro, R | 1 |
| Soulié, P | 1 |
| Fandi, A | 1 |
| Daniel, C | 1 |
| Bedin, A | 1 |
| Doubre, H | 1 |
| Viala, J | 1 |
| Rodier, J | 1 |
| Trandafir, L | 1 |
| Le Chevalier, T | 1 |
| Cvitkovic, E | 1 |
| Armand, J | 1 |
| Saini, A | 1 |
| Webb, A | 1 |
| Gregory, K | 1 |
| Mendes, R | 2 |
| Ryan, C | 1 |
| Bromelow, KV | 2 |
| Palmer, RD | 1 |
| Tuckwell, N | 1 |
| Kennard, DA | 1 |
| Souberbielle, BE | 2 |
| Guaraldi, M | 1 |
| Melotti, B | 1 |
| Pannuti, F | 1 |
| Mitra, A | 1 |
| Gregory, RK | 1 |
| Padhani, AR | 1 |
| Winkley, AR | 1 |
| Riviere, A | 1 |
| Gridelli, C | 1 |
| Pepe, R | 1 |
| Airoma, G | 1 |
| Incoronato, P | 1 |
| Rossi, A | 1 |
| Palazzolo, G | 1 |
| Bianco, AR | 1 |
| Umsawasdi, T | 1 |
| Dhingra, HM | 1 |
| Charnsangavej, C | 1 |
| Luna, MA | 1 |
| Sklarin, NT | 1 |
| Feuer, EJ | 1 |
| Lahman, LA | 1 |
| Hayashi, T | 1 |
| Nasu, Y | 1 |
| Aramaki, K | 1 |
| Johsen, T | 1 |
| Matsuura, H | 1 |
| Asakura, S | 1 |
| Matsui, T | 1 |
| Tatsumi, A | 1 |
| Fujio, A | 1 |
| Kitano, M | 1 |
| Kobashi, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Multicenter Randomized Trial Evaluating the Association of PIPAC and Systemic Chemotherapy Versus Systemic Chemotherapy Alone as 1st-line Treatment of Malignant Peritoneal Mesothelioma[NCT03875144] | Phase 2 | 66 participants (Anticipated) | Interventional | 2020-08-14 | Recruiting | ||
| Cytoreductive Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy for the Treatment of Peritoneal Carcinomatosis From Gastrointestinal Cancer: an Open Label, Randomized, Prospective, Phase 2 Clinical Trial[NCT00454519] | Phase 2 | 60 participants (Anticipated) | Interventional | 2007-03-31 | Recruiting | ||
| A Phase III Randomized Study Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in the Treatment of Relapse Ovarian Cancer[NCT01376752] | Phase 3 | 415 participants (Actual) | Interventional | 2011-04-26 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for mitomycin and Mesothelioma
| Article | Year |
|---|---|
Comprehensive management of diffuse malignant peritoneal mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubicin; H | 2006 |
Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as | 2000 |
[Does treatment for malignant pleural mesothelioma exist?].
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineopl | 2001 |
18 trials available for mitomycin and Mesothelioma
| Article | Year |
|---|---|
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2009 |
Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clin | 2011 |
Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2003 |
Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2003 |
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2004 |
Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Cancer, Regio | 2006 |
Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Therapy, | 2006 |
An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2003 |
Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adju | 2008 |
Experimental and clinical activity of mitomycin C and cis-diamminedichloroplatinum in malignant mesothelioma.
Topics: Aged; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Lin | 1984 |
Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytarabi | 1995 |
Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1996 |
Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Female; Gastrointes | 1997 |
Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Human | 1998 |
Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asbestos; Cisplatin; Combined Modality | 1999 |
A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Vacci | 2000 |
Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Mesothelioma; Methotrexa | 2001 |
Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Vaccines; Cisplatin; Disease-Free Su | 2002 |
28 other studies available for mitomycin and Mesothelioma
| Article | Year |
|---|---|
Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma-A 3-D In Vitro Study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; | 2022 |
Cisplatin exhibits superiority over MMC as a perfusion agent in a peritoneal mesothelioma patient specific organoid HIPEC platform.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Humans; Hypert | 2023 |
Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Colonic Neoplasms; Cy | 2021 |
Outcomes of multicystic peritoneal mesothelioma treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Cytoreduction Surgical Procedures; Doxorubicin; Femal | 2021 |
Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey.
Topics: Antineoplastic Agents; Carcinoma; Cardiac Output; Cisplatin; Colorectal Neoplasms; Cytoreduction Sur | 2018 |
Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; | 2018 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Carcinoma; Colorectal Neoplasms; Co | 2013 |
Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2013 |
Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; | 2014 |
Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Cohort Stu | 2014 |
Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Female; | 2014 |
Utility of Chemoresponse Assay in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytoreductio | 2015 |
The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Cisplatin; Colorectal Neoplas | 2015 |
Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Cisplatin; Cohort Studies; C | 2015 |
Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Combined Mo | 2009 |
Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2010 |
Nonselective transarterial chemoperfusion: a palliative treatment for malignant pleural mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Femal | 2013 |
[New therapeutic options for mesothelioma].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant | 2002 |
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemo | 2005 |
An instrument to provide containment of intraoperative intraperitoneal chemotherapy with optimized distribution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Cisplatin; Containment of Bio | 2005 |
Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 2006 |
Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trial | 2007 |
Aggressive multimodality therapy for malignant pleural mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Feasibility St | 1994 |
Mitomycin C and vindesine: an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; H | 1992 |
A case report of malignant pleural mesothelioma with long-term disease control after chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; | 1991 |
Augmentation of activity of cis-diamminedichloroplatinum(II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Female; Humans; | 1988 |
[A case of peritoneal malignant mesothelioma with disappearance of ascites result of intraperitoneal instillation of mitomycin C and oral administration of UFT].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cryptorch | 1989 |
[A case of malignant pleural mesothelioma and its sensitivity tests for anti-cancer drugs].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug | 1988 |